BAY 58–2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2210
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
BAY 58–2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers ; volume:7 ; number:1 ; day:25 ; month:7 ; year:2007 ; pages:1-2 ; date:7.2007
BMC pharmacology ; 7, Heft 1 (25.7.2007), 1-2, 7.2007
- Urheber
-
Frey, Reiner
Mück, Wolfgang
Unger, Sigrun
Artmeier-Brandt, Ulrike
Weimann, Gerrit
Wensing, Georg
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1471-2210-7-S1-P21
- URN
-
urn:nbn:de:101:1-2019111721005281328345
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Frey, Reiner
- Mück, Wolfgang
- Unger, Sigrun
- Artmeier-Brandt, Ulrike
- Weimann, Gerrit
- Wensing, Georg
- SpringerLink (Online service)
Ähnliche Objekte (12)
BAY 58–2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile
Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
Structural studies of soluble guanylate cyclase
Binding of [3H]BAY 58-2667 to purified bovine lung soluble guanylate cyclase by scintillation proximity assay
Lessons from soluble guanylate cyclase alpha1 knockouts
Molecular steps in soluble guanylate cyclase activation
The role of soluble guanylate cyclase in metabolism
Impact of the nitric oxide-independent soluble guanylate cyclase activator cinaciguat on restenosis after arterial injury in rats
The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus
Role of soluble guanylate cyclase in progressive renal fibrosis
BAY 58–2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile
Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
Structural studies of soluble guanylate cyclase
Binding of [3H]BAY 58-2667 to purified bovine lung soluble guanylate cyclase by scintillation proximity assay
Lessons from soluble guanylate cyclase alpha1 knockouts
Molecular steps in soluble guanylate cyclase activation
The role of soluble guanylate cyclase in metabolism
Impact of the nitric oxide-independent soluble guanylate cyclase activator cinaciguat on restenosis after arterial injury in rats
The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus
Role of soluble guanylate cyclase in progressive renal fibrosis
BAY 58–2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile
Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
Structural studies of soluble guanylate cyclase
Binding of [3H]BAY 58-2667 to purified bovine lung soluble guanylate cyclase by scintillation proximity assay
Lessons from soluble guanylate cyclase alpha1 knockouts
Molecular steps in soluble guanylate cyclase activation
The role of soluble guanylate cyclase in metabolism
Impact of the nitric oxide-independent soluble guanylate cyclase activator cinaciguat on restenosis after arterial injury in rats
The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus